Pb2184 Carfilzomib or Pomalidomide in Patients With Relapse and/or Refractory Multiple Myeloma: Single Center Experience

Abstract

| 2019;3:S1 980 (16.9%), pallor (7.9%), neurological symptoms (5.6%) and finally oliguria (2.2%). CyBorD have better overall response rate (≥PR) (p = 0.031), PFS (p = 0.004) and DFS (p = 0.013) as 1st line treatment compared to VAD regimen. Also in previously treated patients CyBorD showed better PFS (p = 0.039) compared to VAD regimen. There was a significant relation between age (p = 0.001&<0.001) and ASCT (p = 0.001&0.034) with PFS and OS respectively.